Gewinn- und Verlustrechnung von Cardinal Health, Inc.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Abacus FCF Advisors LLC acquired a new position in shares of Cardinal Health, Inc. (NYSE: CAH) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,694 shares of the company's stock, valued at approximately $4,916,000. A number of other

Cardinal Health is rated Buy, driven by robust growth in its Pharmaceutical and Specialty Solutions segment and precision medicine exposure. PSS revenues reached $234.8 billion in FY2026, up 15% YoY, accounting for 92% of CAH's total revenues, with further growth expected from gene therapy and Solaris Health. Precision medicine, growing at a projected 17% CAGR, positions the company to capture a substantial share of an underserved market, supporting long-term top-line expansion.

Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that traders need to see before the open.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

ABN AMRO Bank N.V. purchased a new stake in Cardinal Health, Inc. (NYSE: CAH) during the second quarter, according to its most recent filing with the SEC. The fund purchased 14,130 shares of the company's stock, valued at approximately $3,342,000. Several other hedge funds have also bought and sold shares of CAH. LWM

Cardinal Health (CAH) gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging FY27 outlook.

Cardinal Health delivered FY2026 non-GAAP EPS of $11.26, exceeding initial guidance and achieving over 30% growth, despite a slight revenue miss. CAH's profit mix is shifting toward higher-margin specialty and 'Other' businesses, making traditional distributor revenue metrics less relevant to earnings power. Management guides 13–15% EPS growth for FY2027, with my estimate at $13.10, implying 7–14% upside to a $258–$275 target range.

Cardinal Health (NYSE: CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the quarter, total company revenue rose 6% to $63.7 billion. Gross profit increased 16% to